CHINA-COVID-19-OMICRON-VACCINE-CLINICAL TRIAL (CN)
(220503) -- BEIJING, May 3, 2022 (Xinhua) -- A clinical trial volunteer receives a dose of China's inactivated vaccine against Omicron variants in Hangzhou, east China's Zhejiang Province, May 1, 2022. The inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm was approved for clinical trials by the National Medical Products Administration on April 26. The clinical trials are expected to conclude in three to four months and will be gradually put into use. (Xinhua)
- Product Code
- ILEA000961426
- Registered date
- 2022/5/03 00:00:00
- Credit
- Xinhua / Kyodo News Images
- Media source
- Xinhua News Agency.All Rights Reserved
- Media size
- 2294 × 1529 pixel
- Deployment size
- 1.30(MB)*
*File size when opened in Photoshop, etc.